Lantern Pharma Q2 FY26 operating loss narrows 25% to $3.5 million; net loss widens to $7.1 million

Reuters2026/08/14 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lantern Pharma posted a Q2 2026 net loss of USD 7.1 million, or USD 0.57 per share, widening from USD 4.3 million.
Operating loss narrowed 25% year over year to about USD 3.5 million, while cash and marketable securities totaled about USD 7.4 million.
R&D expense fell 42% to about USD 1.8 million; G&A expense rose 8% to about USD 1.7 million.
Warrant expense totaled about USD 3.6 million, driven mainly by a higher fair value tied to a stock-price increase.
Lantern formed Open Medicine AI as a separate company; LP-300 HARMONIC data showed 8.9-month median PFS in L858R patients completing six cycles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608140730BIZWIRE_USPR_____20260814_BW100282) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lantern Pharma Q2 FY26 operating loss narrows 25% to $3.5 million; net loss widens to $7.1 million

You may also like

Crypto prices